Transforming growth factor beta (TGF-beta) and platelet-derived growth factor (PDGF) are known as protein cytokines involved in differentiation as well as in maturation processes within the hematopoietic system. Both enhance the proliferation and/or collagen synthesis in fibroblasts and are found within the alpha-granules of megakaryocytes. To learn more about the regulation mechanisms involving synthesis and secretion of these cytokines it is important to develop suitable experimental conditions. We have applied the reverse hemolytic plaque assay (RHPA) to CD61+ megakaryocytes prepared from bone marrow of hematologically normal patients. By means of the RHPA, the spontaneous and stimulated secretion of TGF-beta 1 and PDGF could be analyzed at the single cell level. According to morphometric analysis, predominantly small megakaryocytes including precursors (pro- and megakaryoblasts) secrete TGF-beta 1 and PDGF under physiological conditions. Furthermore, the proportion of actively secreting megakaryocytes increased significantly following treatment with recombinant human (rh) IL-3 for 8 h. A slight induction was also appreciated after stimulation with interleukins rhIL-1 or rhIL-11. Because IL-3 as well as IL-11 are known as efficient growth factors for human megakaryocytes in vitro, our data provide insights into the regulatory mechanisms involved in megakaryopoiesis and the development of myelofibrosis.
Download full-text PDF |
Source |
---|
J Clin Oncol
January 2025
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Purpose: Radiotherapy (RT)/cetuximab (C) demonstrated superiority over RT alone for locally advanced squamous head and neck cancer. We tested this in completely resected, intermediate-risk cancer.
Methods: Patients had squamous cell carcinoma of the head and neck (SCCHN) of the oral cavity, oropharynx, or larynx, with one or more risk factors warranting postoperative RT.
Clin Cancer Res
January 2025
The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Purpose: Trastuzumab deruxtecan (T-DXd) is currently approved for treating metastatic breast cancer (MBC) which is HER2-positive (immunohistochemistry [IHC] score of 3+ or ISH positivity) or HER2-low (IHC score of 1+ or IHC 2+/ISH negative), as well as for HER2-positive gastric cancer, HER2-mutant lung cancer, and HER2 overexpressing solid tumors. Given the increasing utilization of T-DXd, we sought to determine how HER2 receptor status might change following T-DXd therapy.
Design: We retrospectively reviewed patients with MBC who received T-DXd at The University of Texas MD Anderson Cancer Center.
Sci Adv
January 2025
Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Mitochondrial electron transport chain (ETC) function modulates macrophage biology; however, mechanisms underlying mitochondria ETC control of macrophage immune responses are not fully understood. Here, we report that mutant mice with mitochondria ETC complex III (CIII)-deficient macrophages exhibit increased susceptibility to influenza A virus (IAV) and LPS-induced endotoxic shock. Cultured bone marrow-derived macrophages (BMDMs) isolated from these mitochondria CIII-deficient mice released less IL-10 than controls following TLR3 or TLR4 stimulation.
View Article and Find Full Text PDFSci Adv
January 2025
School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, Ireland.
The cytokine interleukin-10 (IL-10) limits the immune response and promotes resolution of acute inflammation. Because of its immunosuppressive effects, IL-10 up-regulation is a common feature of tumor progression and metastasis. Recently, IL-10 regulation has been shown to depend on mitochondria and redox-sensitive signals.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!